bioMérieux's Stock Plummets Over 40% in a Year and Tests its 20-Day Moving Average
In a declining Parisian market, heavily influenced by tensions in the Middle East, bioMérieux's stock falls during the session. The Lyon-based company is facing a lowered price target from a major American brokerage, adding to an already significantly deteriorated stock trajectory over the past twelve months.
BofA Lowers Price Target to €80 While Maintaining a Hold Rating
Yesterday, BofA Securities reduced its price target on bioMérieux to €80 from €85 previously. The American firm maintains its neutral stance on the stock. At €69.00, the new target offers a theoretical potential of nearly 16%, but the adjustment reflects a downward revision of the expected valuation by the analysts. The market context is not helping: the CAC 40 is down nearly 2% and the SBF 120 is declining in similar proportions, while the VIX spikes over 11% amid military escalation between the United States and Iran.
The Stock Revisits its 20-Day Moving Average at €68.92 After a Year-Long Decline of Over 42%
At €69.00, the stock is precisely at its 20-day moving average (€68.92), which now plays a pivotal role after a rebound that began in early July. The stock remains below its 50-day moving average at €70.80 (a gap of -2.54%) and far below its 200-day moving average at €94.55, with a gap of -27% that illustrates the depth of the decline since last year. The RSI at 53 remains in a neutral zone, without a clear directional signal. The loss stands at 5.3% over a month and 42.1% over a year, while the weekly performance remains almost flat. The support at €66.60 is the next numerical threshold to watch if the 20-day moving average were to give way.
